Free Trial
NASDAQ:DRUG

Bright Minds Biosciences (DRUG) Stock Price, News & Analysis

Bright Minds Biosciences logo
$33.42 -0.68 (-1.99%)
As of 04/24/2025 04:00 PM Eastern

About Bright Minds Biosciences Stock (NASDAQ:DRUG)

Key Stats

Today's Range
$33.23
$34.73
50-Day Range
$28.19
$37.51
52-Week Range
$0.93
$79.02
Volume
23,835 shs
Average Volume
820,437 shs
Market Capitalization
$235.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$84.33
Consensus Rating
Buy

Company Overview

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Bright Minds Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
67th Percentile Overall Score

DRUG MarketRank™: 

Bright Minds Biosciences scored higher than 67% of companies evaluated by MarketBeat, and ranked 449th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bright Minds Biosciences has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bright Minds Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Bright Minds Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Bright Minds Biosciences are expected to decrease in the coming year, from ($1.24) to ($3.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bright Minds Biosciences is -196.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bright Minds Biosciences is -196.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bright Minds Biosciences has a P/B Ratio of 5.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Bright Minds Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    2.03% of the float of Bright Minds Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Bright Minds Biosciences has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bright Minds Biosciences has recently decreased by 8.20%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bright Minds Biosciences does not currently pay a dividend.

  • Dividend Growth

    Bright Minds Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.03% of the float of Bright Minds Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Bright Minds Biosciences has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bright Minds Biosciences has recently decreased by 8.20%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Bright Minds Biosciences has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Bright Minds Biosciences this week, compared to 1 article on an average week.
  • Search Interest

    39 people have searched for DRUG on MarketBeat in the last 30 days. This is an increase of 255% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Bright Minds Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bright Minds Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    42.66% of the stock of Bright Minds Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    40.52% of the stock of Bright Minds Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bright Minds Biosciences' insider trading history.
Receive DRUG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter.

DRUG Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Bright Minds Biosciences expands Scientific Advisory Board
Bright Minds Biosciences (DRUG) Receives a New Rating from Piper Sandler
See More Headlines

DRUG Stock Analysis - Frequently Asked Questions

Bright Minds Biosciences' stock was trading at $36.02 on January 1st, 2025. Since then, DRUG stock has decreased by 7.2% and is now trading at $33.42.
View the best growth stocks for 2025 here
.

Bright Minds Biosciences Inc. (NASDAQ:DRUG) announced its earnings results on Thursday, February, 13th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.24.

Shares of Bright Minds Biosciences reverse split before market open on Friday, July 14th 2023. The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bright Minds Biosciences investors own include HubSpot (HUBS), Blink Charging (BLNK), ConocoPhillips (COP), Netflix (NFLX), ForgeRock (FORG) and SoFi Technologies (SOFI).

Company Calendar

Last Earnings
2/13/2025
Today
4/24/2025
Next Earnings (Estimated)
5/21/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DRUG
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$84.33
High Stock Price Target
$93.00
Low Stock Price Target
$75.00
Potential Upside/Downside
+152.3%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-2,060,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$5.86 per share
Price / Book
5.70

Miscellaneous

Free Float
4,039,000
Market Cap
$235.41 million
Optionable
Not Optionable
Beta
-5.50
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:DRUG) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners